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Abstract
A chemical approach for selective masking of arginine residues on viral capsids, featuring an
exogenous glycation reaction has been developed. Reaction of adeno-associated viral (AAV)
capsids with the α-dicarbonyl compound, methylglyoxal resulted in formation of arginine adducts.
Specifically, surface exposed guanidinium side chains were modified into charge neutral
hydroimidazolones, thereby disrupting a continuous cluster of basic amino acid residues
implicated in heparan sulfate binding. Consequent loss in heparin binding ability and decrease in
infectivity were observed. Strikingly, glycated AAV retained ability to infect neurons in the mouse
brain and were redirected from liver to skeletal and cardiac muscle following systemic
administration in mice. Further, glycated AAV displayed altered antigenicity demonstrating
potential for evading antibody neutralization. Generation of unnatural amino acid side chains
through capsid glycation might serve as an orthogonal strategy to engineer AAV vectors
displaying novel tissue tropisms for gene therapy applications.
Protein engineering tools have played a central role in understanding structure-function
correlates of viruses (1, 2). The application of site directed mutagenesis to elucidate the
structural basis of virus-receptor interactions is particularly noteworthy in this regard (3, 4).
Altering virus-receptor interactions by selective incorporation of unnatural amino acids or
chemical masking of amino acid residues, exposed on the viral capsid surface could greatly
expand the ability to discover receptor footprints on viral capsid surfaces as well as design
new viral vectors and vaccines.
Several studies exploring the genetic incorporation of unnatural amino acids and/or
chemoselective ligation to viral capsids have been reported (5). For instance, viral capsids
containing unnatural amino acids with alkyne (5), azide (5) or aminophenyl (6) side chains
have been generated for coupling of drugs and/or targeting ligands. Synthetic strategies for
chemoselective ligation to naturally occurring amino acid residues such as Lys, Glu, Cys,
Trp and Tyr on the surface of viral capsids have also been developed (7–11). However, the
application of such chemistries towards reengineering viruses for gene delivery remains
unexplored thus far.
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In the current study, we focused on exploiting the naturally occurring chemical reaction
involving α-dicarbonyl compounds with proteins, which leads to the formation of advanced
glycation endproducts (AGE)(12). We hypothesized that methylglyoxal, an intermediate of
the Maillard reaction, will selectively form adducts with guanidinium side chain of surface
exposed Arg residues on viral capsids (Scheme 1). The reaction proceeds readily in aqueous
solution and has been shown to predominantly modify Arg residues in various proteins with
high efficiency. Proteomic analysis of Arg adducts has previously demonstrated the
formation of dihydroxyimidazolidines followed by subsequent rearrangement into
hydroimidazolones (13, 14).
AAV is a small non-enveloped ssDNA virus that is rapidly gaining momentum as a vector in
human gene therapy applications (15). The AAV capsid is comprised of 60 capsid protein
subunits assembled in icosahedral symmetry (T=1). Each capsid protein subunit contains a
β-barrel core with long loops between the β-strands that create striking surface features.
Surface spikes located at the three-fold symmetry axes are most prominent and have been
implicated in receptor binding and cell entry. The remarkable plasticity of the AAV virion
shell has been demonstrated through extensive mutagenesis studies (15).
Of several strains isolated to date, AAV serotype 2 is the most studied and binds to its
primary receptor heparan sulfate using a basic cluster of amino acids (R484, R487, K532,
R585, and R588) located at the three-fold axis of symmetry (16, 17). Previous site directed
mutagenesis studies have demonstrated the critical role played by this continuous basic
patch in cell surface recognition as well as liver tropism in mice (18, 19). In particular,
mutation of Arg residues within this basic cluster has been shown to confer muscle tropism.
However, the potential for generating atypical tissue tropisms through the latter approach is
restricted by the ability to only incorporate naturally occurring amino acids with limited side
chain diversity.
We hypothesized that an orthogonal approach based on selective chemical masking of Arg
residues with α-dicarbonyl compounds would enable display of unnatural amino acid
residues with diverse functional groups on the AAV capsid surface. Such modification of
amino acid side chains might enable design of viral vectors displaying atypical tissue
tropisms. As proof of principle, we chose methylglyoxal (MGO), a highly reactive
compound derived from glycolysis and known for its propensity to form Arg and Lys
adducts (14). It should be noted that chemical conjugation to Lys residues on AAV2 capsids
are routinely carried out and demonstrate no adverse effect on capsid infectivity (20).
Overnight reaction of AAV2 with methylglyoxal at neutral pH produced glycated AAV
vectors. Characterization of the glycated vectors was carried out using MALDI-TOF/MS of
trypsin-treated capsid proteins. Rationale for such analysis is based on earlier observations
that altered tryptic digestion of glycated proteins enables proteomic analysis of MGO
adducts (13). Tryptic fragments obtained from the major AAV capsid protein subunit (VP3;
Genbank# AAC03779.1) were subject to MALDI-TOF/MS analysis. Peak signals were
normalized to that of a peptide fragment located within the capsid interior (16) containing
residues L299 through K309 (m/Z = 1375.7), which are expected to remain unmodified
when subject to glycation. Analysis of mass spectra using the MASCOT search engine
revealed a decrease in peak signal intensities corresponding to peptide fragments containing
Arg residues and, to a lesser extent, Lys residues (Supporting Information). Specifically, the
MGO-derived hydroimidazolone adduct is expected to add 54 m/Z units to the modified
peptide fragment. New peak signals, observed between m/Z 2400 and 2600 were
specifically assigned to peptide fragments containing hydroimidazolone adducts at R585 and
R459 positions (Figure 1a). Computation of the ratio of peak signal intensities pertaining to
the latter residues before and after glycation indicates that 29.5% of R585 and 58.9% of
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R459 residues are glycated. Although the latter results indicate the potential formation of
mixtures of variably glycated capsids and are semi-quantitative in nature, we have optimized
chemical modification of AAV vectors to consistently generate the same phenotype
(Supporting Information). Moreover, the aforementioned results are in agreement with
earlier studies and corroborate the notion that surface-exposed Arg residues on proteins are
preferred targets for glycation (13, 14).
The ability of glycated AAV2 to bind heparin was determined using a streptavidin-coated
96-well assay plate coated with biotinylated heparin. Binding was determined using Q-PCR
and binding to biotinylated dextran was utilized as a control. Glycated AAV2 capsids
display a significant loss (p < 0.05) in heparin binding ability in comparison with
unmodified AAV2 capsids (Figure 1b). Further, MGO-modified AAV2 vectors demonstrate
an approximately 1000-fold decrease in gene transfer efficiency in HEK293 cells (Figure
1c). These results corroborate the notion that glycated AAV2 is unable to bind its cognate
attachment receptor, heparan sulfate (21). Of the five residues (R484, R487, K532, R585,
and R588) located within the heparan sulfate receptor footprint, R585 or R588 have been
shown to be indispensable for heparin binding and infectivity (18, 19). Taken together with
MS data, the aforementioned results suggest that conversion of the guanidinium side chain
of R585 into the hydroimidazolone derivative likely disrupts the heparan sulfate footprint on
the AAV2 capsid surface. It should also be noted that although glycation of R459 was
observed, this residue has not been implicated in heparin binding or infectivity (18, 19).
Another observation supporting the chemical masking of arginine residues within surface-
exposed domains is the altered antigenicity of glycated AAV2 vectors. Using a solid phase
binding assay, we determined that MGO-modified AAV2 vectors showed a > 2-fold
decrease in binding to a prototypical monoclonal antibody (A20), which recognizes intact
AAV2 capsids (Figure 1d). An isotype matched antibody served as control. These results
indicate the potential for glycated AAV vectors to evade pre-existing neutralizing antibodies
in the human population (22).
Despite demonstrating decreased infectivity in vitro, glycated AAV2 capsids infect neurons
as efficiently as untreated AAV2 following intracranial injection into the mouse brain
(Figure 2). Taken together with the altered antigenicity described earlier; these results
suggest that glycated AAV2 vectors might be well suited for CNS gene transfer
applications. Further, bioluminescent images of mice obtained following intravenous (tail
vein) administration of glycated AAV2 show expansion of viral tissue tropism beyond the
liver to other systemic organs (Figure 2c). Quantitation of luciferase expression in tissue
lysates reveals approximately 100-fold higher transgene expression levels in cardiac and
skeletal muscle with MGO-treated AAV2 in comparison with untreated AAV2 vectors
(Figure 2d). In addition, a concomitant decrease in transgene expression within the liver
(over 10-fold) is observed. These results demonstrate the feasibility of chemical redirection
of AAV2 capsids from liver to muscle tissue and corroborate a similar transduction profile
obtained by mutagenesis of R585/R588 residues within the heparan sulfate footprint (19,
23).
In conclusion, the aforementioned studies validate the notion that selective chemical
masking of Arg residues with α-dicarbonyl compounds can serve as an orthogonal approach
to reengineer viral surface topology and consequently, antigenicity, receptor usage and
tissue tropism. This initial study is one of the first to demonstrate feasibility of displaying
unnatural hydroimidazolone side chains on viral capsids. A broad range of α-dicarbonyl
compounds ranging from glyoxal to oxo-(7-oxoacetyl-9H-fluoren-2-yl)-acetaldehyde are
currently being explored for formation of diverse Arg adducts on AAV capsids. An increase
in complexity of the α-dicarbonyl side chain may allow generation of novel tissue tropisms,
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while simultaneously enabling design of AAV vectors with capable of evading neutralizing
antibodies. This chemical approach represents a new dimension in viral capsid engineering
and is likely to impact viral vector design for human gene therapy applications.
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a) Tryptic digestion of chemically modified AAV2 VP3 capsid proteins demonstrates two
preferred sites for Arg adduct formation. The increase in signal at m/Z 2446.1 and 2577.2
corresponds to the hydroimidazolone adduct at R585 and R459 positions within the peptides
566-TTNPVATEQYGSVSTNLQRGNR-588 (expected adduct m/Z = 2446.173) and 448-
TNTPSGTTTQSRLQFSQAGASDIR-471 (expected adduct m/Z = 2577.231), respectively.
b) Solid phase binding assay of unmodified and glycated AAV2 capsids to heparin-coated
plates. Binding is relative to the charge neutral dextran. c) In vitro infectivity assay of
unmodified and glycated AAV2 in HEK293 cells (10,000 viral genomes/cell). d) Solid
phase binding assay of unmodified and glycated AAV2 capsids to plates coated with the
monoclonal antibody A20. Binding is relative to an isotype-matched antibody control. Error
bars represent standard deviation (n = 3). Asterisks represent statistical significance (p <
0.05). Additional experimental details available in Supporting Information.
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Epifluorescence images of neuronal GFP expression in 40 μm brain sections obtained from
BALB/c mice injected intracranially with 7.5×108 a) untreated AAV2 and b) MGO-treated
AAV2 vectors. Brain sections were taken 2 weeks post-injection and stained with DAPI
prior to imaging. c) Live animal bioluminescent images of BALB/c mice (n = 3) injected
with untreated and MGO-treated AAV2 vectors. Mice were injected via tail vein at a dose of
5×1010 viral particles. Mice were imaged 4 weeks post-injection. Changes in luciferase
expression patterns indicate altered tissue tropism profiles and are represented on a rainbow
scale. d) Luciferase expression from untreated and MGO-treated AAV2 vectors in different
tissue lysates. Relative light units represent luciferase transgene expression and levels are
normalized to tissue mass. Error bars represent standard deviation (n = 3). Asterisks
represent statistical significance (p < 0.05). Additional experimental details available in
Supporting Information.
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Glycation of AAV vectors with methylglyoxal
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